MIB Agents Osteosarcoma Alliance

Yesterday, we were joined by Brigitte Brisson, DMV, DVSc, DACVS, on OsteoBites to discuss, "Magnetic Resonance Guided (MRg) High Intensity Focused Ultrasound (HIFU) For Palliation of Canine Appendicular Osteosarcoma". Watch the full episode here: https://lnkd.in/gXcXS5Hq Dr. Brigitte Brisson is a professor of soft tissue surgery in the Department of Clinical Studies at the Ontario Veterinary College (OVC). She graduated from the Faculté de Médecine Vétérinaire at the University of Montreal in 1996. She performed a small animal rotating internship at the OVC followed by a Surgery residency with concurrent Doctor of Veterinary Science (DVSc) in small animal surgery. She became board certified in small animal surgery (ACVS) in 2001 and has since been on faculty at the Ontario Veterinary College. She is an ACVS Founding Fellow in Minimally Invasive Surgery and a Founding Member of Veterinary Neurosurgical Society.Her clinical interest is in soft tissue surgery, including oncology and neurosurgery with a specific interest for minimally invasive and interventional procedures. Dr. Brisson’s research has focused on canine intervertebral disc disease, innovative minimally invasive and interventional surgical procedures and osteosarcoma. She is currently collaborating with a group of paediatric surgeons and interventionalists to develop novel treatment options for canine and paediatric cancers. Dr. Brisson has been invited to present the results of her research and other CE around world and has published over 70 articles in refereed journals, authored several book chapters and is the co-editor of Wiley’s Current Techniques in Canine and Feline Neurosurgery textbook #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

Truly, Smart Patients #MakeItBetter through community, shared experience, and wholehearted support of each other. Grateful are we to be together in support of each other!

"Ann Graham changed the direction of her career after being treated for osteocarcoma - a type of cancer that usually affects children and young people" 🎗MIB Agents' founder, Ann Graham, was recently featured in an Outsourcing-Pharma article, "Ann Graham from her shocking cancer diagnosis to supporting youngsters battling the disease". 🎗Read the full article here: https://lnkd.in/g-4JTXvZ #MIBAgents #MakeItBetter #osteosarcoma #OutSourcingPharma #article

Got a bike? Use your Pedals for Good on Sunday, September 1st to #MakeItBetter for kids with bone cancer. This ride is organized by Sherrick Murdoff, Board Member of MIB Agents and, most importantly, Dad to Charlotte. Charlotte was one of the most incredible humans to walk this earth. While in treatment, she made unique, beautiful, and very cool sweatshirts to help other kids she was treated with. Proceeds from the sale went to fund research for #Osteosarcoma, the cancer that would take her life in 2021 at age 18. She also served on our Junior Board. Her courage, fortitude, and grace were astonishing - even showing up for a Jr. Board meeting two days after a 20-hour lung surgery. Char continues to inspire us and anyone who knows her story. Her twin brother, sister, and parents continue her astonishing legacy with events like this, which fund research #BecauseOfCharlotte. If you cannot ride, then consider writing a check or donating on the link. It matters. So much.

Yesterday, we were joined by Diana Azzam, PhD, on OsteoBites to discuss, "Clinical Utility of Functional Precision Medicine to Guide Treatments for Osteosarcoma Patients". Watch the full episode here: https://lnkd.in/gKzu43f2 Diana Azzam, PhD, is an Assistant Professor and Research Director of the Center for Advancing Personalized Cancer Treatments at Florida International University. She has a Masters in Biochemistry from the American University of Beirut, Lebanon and a PhD in Biochemistry & Molecular Biology from the University of Miami, Florida. Her lab focuses on implementing functional precision medicine (FPM) approaches in adult and pediatric cancer patients that have run out of treatment options. Working with local hospitals including Nicklaus Children’s Hospital and Cleveland Clinic Florida, her lab delivers individualized treatment plans based on a patient’s cancer genomic profile and ex vivo drug response. She is currently engaged in two clinical studies to assess feasibility and clinical utility of FPM in relapsed/refractory patients with childhood cancer (ClinicalTrials.gov registration: NCT05857969) and adult cancer (ClinicalTrials.gov registration: NCT06024603). Dr. Azzam is working on setting up the first CLIA-certified lab in the State of Florida dedicated for functional cancer drug testing. Her goal is to launch large-scale prospective multi-center randomized clinical trials to better assess efficacy of FPM approaches in the treatment of refractory/relapsed cancers. In parallel, she is working on utilizing FPM as a tool to reduce health disparities in childhood cancer patients from minority populations. She is also integrating a novel machine learning approach to identify specific biomarkers among minority populations that can be targeted using FDA-approved drugs. Her lab also investigates cancer stem cells and how they may result from chronic environmental exposures to toxic metals such as arsenic. #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

NEW: Outsourcing Pharma Webinar! ⭐"FDA guidance about improving diversity in studies has gained momentum and continues to do so. It has always been a goal of nearly every clinical research professional, but achieving it has been historically difficult, how has this changed since the guidance was issued. This webinar will discuss some of major changes but also the key obstacles that still stand in the way" ⭐Our very own Ann Graham was featured as a speaker on this Outsourcing Pharma Webinar! ⭐Watch/listen here: https://lnkd.in/gJNF36FN #MIBAgents #MakeItBetter #osteosarcoma #OutsourcingPharma

Thursday, we were joined by Sabina Kaczanowska, PhD, on OsteoBites to discuss, "Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy". Watch the full episode here: https://lnkd.in/gXKnw6Tt Dr. Sabina Kaczanowska received her Ph.D. in Molecular Microbiology and Immunology from the University of Maryland, Baltimore in for her dissertation work on T cell immunotherapy in the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center. She joined the Tumor Microenvironment and Metastasis Section of Pediatric Oncology Branch at the National Cancer Institute as a postdoctoral fellow in 2017 with Dr. Rosandra Kaplan. Dr. Kaczanowska’s research focus is to understand the role of the immune system in shaping the microenvironment of metastasis during cancer progression. Specifically, she is investigating how myeloid cells orchestrate the immunosuppressive program in cancer and how we can apply this knowledge of myeloid biology to design new immunotherapeutic strategies for the treatment of solid tumors. Dr. Kaczanowska was appointed as a Staff Scientist in the Pediatric Oncology Branch in 2022 to continue her work evaluating the responses of solid tumor patients to immunotherapy and translating new immuno-oncology approaches into the clinic. #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

Yesterday, we were joined by Bhuvana Setty, MD, on OsteoBites to discuss, "A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue (TINKS)" Watch the full episode here: https://lnkd.in/gc-SN4kh Bhuvana Setty, MD, is a Pediatric Hematologist/Oncologist at Nationwide Children's Hospital. Her clinical interests include treating pediatric and young adult patients with bone and soft tissue sarcomas, and patients with vascular anomalies. She is the Director of the Clinical Sarcoma Team. She is the Site Principal investigator for the Sunshine Project supported by the National Pediatric Cancer Foundation and serves as the lead for the Ewing sarcoma Task Force at the Sunshine Project. In addition, she is the Site Principal Investigator for The Sunshine Project, an early phase clinical trial consortium and CaNVAS, the Consortium of iNvestigators for Vascular Anomalies. Her research interests include developing translational and therapeutic clinical trials with novel agents for patients with aggressive bone and soft tissue sarcomas. She leads as National PI for the TINKS trial as well as the upcoming metastatic Ewing sarcoma trial at the Children's Oncology Group. #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

AIRING TODAY! "The Sibling Situation" Christopher Kuo osTEAo: The Osteosarcoma Podcast, is a podcast dedicated to demystifying life with cancer and illness, from the perspective of AYA patients. Panelists consist of patients, siblings, and caregivers affected by Osteosarcoma who are occasionally joined with healthcare experts to talk all things AYA cancer. WATCH HERE: https://lnkd.in/gC6UMeuT #osteosarcoma #ayacancer #ayacancerpodcast #osteosarcomapodcast #osTEAo #spillingthetea

Thursday, we were joined by Olivier Elemento, PhD, on OsteoBites to discuss, "Genomes, Avatars and AI: The Future of Personalized Medicine" Watch the full episode here: https://lnkd.in/g-jEAbyQ Olivier Elemento, PhD, is a professor of physiology and biophysics at Weill Cornell Medicine. Since 2017, he has been the Director of the Caryl and Israel Englander Institute for Precision Medicine, a large multi-disciplinary institute that uses precision medicine technologies and informatics to uncover the molecular mechanisms of disease and individualize disease treatment and prevention. He is also the Associate Director of the Institute for Computational Medicine, Director of the Laboratory of Cancer Systems Biology, Co-Leader of the Genetics, Epigenetics, and Systems Biology Program in the Meyer Cancer Center at Weill Cornell Medicine. His research group combines Big Data, Artificial Intelligence with experimentation and genomic profiling to accelerate the discovery of cancer cures. #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast